Skip to main content
SpringerLink
Log in

Myxoid/Round Cell Liposarcoma

  • Chapter
  • First Online:
Soft Tissue Tumors

  • 82 Accesses

Abstract

Myxoid/round cell liposarcoma is a malignant tumor of adipocytic origin. This entity is also known as myxoid liposarcoma and includes the more cellular neoplasm formerly known as round cell liposarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    FUS-DDIT3 fusion gene: FUS (fused in sarcoma; also known as translocated in liposarcoma, TLS) encodes for a protein belonging to the FET family of RNA-binding proteins (implicated in regulation of gene expression and mRNA/microRNA processing). DDIT3 (DNA damage inducible transcript 3; also known as C/EBP-homologous protein, CHOP) encodes a member of the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors. The FUS-DDIT3 fusion protein is believed to confer tumorigenicity through dysregulation of adipocyte differentiation, leading to unchecked proliferation of immature lipoblasts that are incapable of differentiating. FUS is involved also in the FUS-DDIT3 fusion gene, which is characteristic of myxoid liposarcoma.

Suggested Readings

  • Antonescu (2001) Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7(12):3977–3987

    CAS  PubMed  Google Scholar 

  • Assi (2019) A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. Cancer Treat Rev 72:37–44

    Article  CAS  Google Scholar 

  • Chowdhry (2018) Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy. Sarcoma 2018:8029157

    Article  Google Scholar 

  • Chung (2009) Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer 115(14):3254–3261

    Article  Google Scholar 

  • Crago (2016) Liposarcoma: multimodality management and future targeted therapies. Surg Oncol Clin N Am 25(4):761–773

    Article  Google Scholar 

  • Fletcher (2020) WHO classification of tumours of soft tissue and bone (5th edition)

    Google Scholar 

  • Gorelik (2018) Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. Skelet Radiol 47(3):369–379

    Article  Google Scholar 

  • Gouin (2019) Early detection of multiple bone and extra-skeletal metastases by body magnetic resonance imaging (BMRI) after treatment of Myxoid/Round-Cell Liposarcoma (MRCLS). Eur J Surg Oncol 45(12):2431–2436

    Article  Google Scholar 

  • Gronchi (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18(6):812–822

    Article  CAS  Google Scholar 

  • Grosso (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8(7):595–602

    Article  CAS  Google Scholar 

  • Jones (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41(18):2853–2860

    Article  CAS  Google Scholar 

  • Muratori (2018) Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution. Int J Surg Oncol 2018:8928706

    PubMed  PubMed Central  Google Scholar 

  • Pollack (2020) Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. [Epub ahead of print]

    Google Scholar 

  • Sonoda (2019) Giant myxoid liposarcoma of the stomach: report of a case. Int J Surg Case Rep 60:234–238

    Article  Google Scholar 

  • Tornin (2018) FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway. Neoplasia 20(1):44–56

    Article  CAS  Google Scholar 

  • Trautmann (2017) FUS-DDIT3 fusion protein-driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma. Clin Cancer Res 23(20):6227–6238

    Article  CAS  Google Scholar 

  • Trautmann (2019) Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma. Mol Cancer Ther 18(4):834–844

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy

    Simone Mocellin

  2. Melanoma and Soft Tissue Sarcoma Unit, Istituto Oncologico Veneto (IOV-IRCCS) of Padova, Padova, Italy

    Simone Mocellin

Authors
  1. Simone Mocellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Mocellin .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mocellin, S. (2021). Myxoid/Round Cell Liposarcoma. In: Soft Tissue Tumors . Springer, Cham. https://doi.org/10.1007/978-3-030-58710-9_182

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-58710-9_182

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-58709-3

  • Online ISBN: 978-3-030-58710-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation